We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
evocatal Invests in High-Throughput Technology and Multiplies its Screening Capacity
News

evocatal Invests in High-Throughput Technology and Multiplies its Screening Capacity

evocatal Invests in High-Throughput Technology and Multiplies its Screening Capacity
News

evocatal Invests in High-Throughput Technology and Multiplies its Screening Capacity

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "evocatal Invests in High-Throughput Technology and Multiplies its Screening Capacity"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The evocatal GmbH puts its new high-throughput screening lab located in the Life-Science Centre Duesseldorf into operation. The enzyme and fine chemicals specialist multiplies its capacity for the development of new enzymes with this step. Accordingly the time-to-market period is shortened through automization.

Together with the scientific advisory board and evocatal’s 17-strong team CSO Dr. Christian Leggewie opens up the newly established high-throughput laboratory in the Life Science Centre Duesseldorf.

One of the pioneers in development and successful use of automated high- and ultrahigh-throughput technology in the field chiral synthesis of ultrapure fine chemicals is Prof. Manfred T. Reetz, who chairs evocatal’s scientific advisory board since 2008. “Not at least for this reason our HTS-lab will carry the name of our advisory board’s chairman”, CEO Dr. Thorsten Eggert comments the dedication.

The investment enables evocatal to reduce development periods for customized biocatalysts immensely. This applies for projects with cooperation partners as well as for supplying efficient enzymes for the internal production of fine chemicals.

“Due to the Prof.-Reetz-Lab our customers will get a faster access to our comprehensive metagenome and enzyme libraries”, says Dr. Michael Puls, Managing Director and CMO of evocatal. “A short time-to-market is of utmost significance – thus we can now ensure our customers a long-term advantage in competition by automizing our development processes”, adds Dr. Puls.

evocatal develops and produces biocatalysts for the chemical and pharmaceutical industry. Performing contract research (CR) or producing its own enzymes and biocatalytic processes, the company continuously strives to improve its customer´s businesses.
Advertisement